脊索瘤免疫治疗的研究进展及展望
| 作者: |
1马小雨,
2汪展辉,
1钟南哲,
1矫健
1 上海长征医院骨肿瘤外科，上海 200003 2 上海长征医院胰胆外科，上海 200003 |
| 通讯: |
钟南哲
Email: nanzhezhong@outlook.com 矫健 Email: jkjj1981@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2020.12.033 |
| 基金: | 国家自然科学基金委员会资助项目(81902731)。 |
摘要
脊索瘤是一种较少见的原发低度恶性骨肿瘤。手术整体切除是目前主要治疗方式，但其对化疗、放疗、及靶向治疗敏感性较低，患者术后复发率高，预后较差。目前免疫治疗在部分肿瘤中取得较好的疗效，也成为了脊索瘤保守治疗的重要研究方向。本文重点从免疫检查点阻断、嵌合抗原受体和肿瘤抗原疫苗等方面介绍免疫疗法应用于脊索瘤治疗的研究进展，并展望其发展方向。
关键词：
脊索瘤；免疫治疗；免疫检查点；嵌合抗原受体；肿瘤抗原疫苗
Advances and prospective in immunotherapy for chordoma
CorrespondingAuthor: ZHONG Nanzhe Email: nanzhezhong@outlook.com
DOI: 10.3978/j.issn.2095-6959.2020.12.033
Foundation: This work was supported by the National Natural Science Foundation of China (81902731).
Abstract
Chordoma is a very rare, primary and low-grade tumors of the bone. The mainstay of treatment for chordoma is en bloc resection, but chordomas are largely insensitive to radiation, chemotherapy and targeted therapy, with highly recurrence and poor prognosis. Emerging immunotherapy have generated attention for their efficiency in a part of human cancers, which has led to interests in developing conservative treatment to chordoma. This review focused on the progress of immunotherapy for chordoma, including immune checkpoint blockade, chimeric antigen receptors, and tumor antigen vaccines, and providing future prospective.
Keywords：
chordoma; immunotherapy; immune checkpoint blockade; chimeric antigen receptors; tumor antigen vaccines